RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PCI Biotech Holding A Stock

PCI Biotech Holding A ROE 2024

PCI Biotech Holding A ROE

-0.52

Ticker

PCIB.OL

ISIN

NO0010405640

WKN

A0Q2FS

In 2024, PCI Biotech Holding A's return on equity (ROE) was -0.52, a -45.79% increase from the -0.96 ROE in the previous year.

PCI Biotech Holding A Aktienanalyse

What does PCI Biotech Holding A do?

PCI Biotech Holding ASA is a biopharmaceutical company based in Norway that focuses on the clinical development of drugs based on the so-called "Photochemical Internalization" (PCI) technology. The company was founded in 2000 as a spin-off from the Norwegian Cancer Society. The PCI technology, which is based on the use of light and chemicals to transport drugs into cells, was developed by Norwegian researchers in the 1990s. Since then, PCI Biotech has been working in collaboration with various research institutions and pharmaceutical companies to optimize this technology and advance its application in medicine. PCI Biotech's business model is based on providing its PCI technology and expertise to partners in research and industry. At the same time, the company also conducts its own clinical research on drugs based on the PCI technology. The goal is to develop drugs that are effective in various forms of cancer and other serious diseases. PCI Biotech is divided into two main divisions: the project department, which works on the development of its own drugs, and the service department, which licenses its PCI technology to third parties. One significant product of the project department is the drug "Amphinex," which is used in the treatment of pancreatic cancer. Amphinex is administered to patients in combination with chemotherapy to enhance the effectiveness of the chemotherapy. Amphinex activates the PCI technology in cancer cells, thereby facilitating the penetration of the chemotherapeutic agent into the cells. Other projects in the company's pipeline include drugs for the treatment of prostate cancer and skin cancer, as well as targeted destruction of tumor cells in the brain. The service department offers various solutions for the academic and industrial sectors. The PCI technology can be used in the development of drugs for the treatment of other diseases, such as viral infections or inflammatory diseases. Furthermore, the PCI technology can also be utilized in imaging or diagnostics. Overall, PCI Biotech is a company specialized in the development of innovative drugs. By using the PCI technology, drugs can be delivered more specifically and effectively into cells, opening up new possibilities in cancer treatment and other areas of medicine. PCI Biotech has become a significant player in clinical research in recent years and works closely with other research institutions and pharmaceutical companies to optimize their technology and explore new application areas. PCI Biotech Holding A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding PCI Biotech Holding A's Return on Equity (ROE)

PCI Biotech Holding A's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing PCI Biotech Holding A's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

PCI Biotech Holding A's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in PCI Biotech Holding A’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about PCI Biotech Holding A stock

What is the ROE (Return on Equity) of PCI Biotech Holding A this year?

The ROE of PCI Biotech Holding A this year is -0.52 undefined.

How has the Return on Equity (ROE) of PCI Biotech Holding A developed compared to the previous year?

The ROE of PCI Biotech Holding A has increased by -45.79% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of PCI Biotech Holding A?

A high ROE indicates that PCI Biotech Holding A generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of PCI Biotech Holding A?

A low ROE can indicate that PCI Biotech Holding A is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of PCI Biotech Holding A affect the company?

A change in ROE (Return on Equity) of PCI Biotech Holding A can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of PCI Biotech Holding A?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of PCI Biotech Holding A?

Some factors that can influence PCI Biotech Holding A's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does PCI Biotech Holding A pay?

Over the past 12 months, PCI Biotech Holding A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PCI Biotech Holding A is expected to pay a dividend of 0 NOK.

What is the dividend yield of PCI Biotech Holding A?

The current dividend yield of PCI Biotech Holding A is .

When does PCI Biotech Holding A pay dividends?

PCI Biotech Holding A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PCI Biotech Holding A?

PCI Biotech Holding A paid dividends every year for the past 0 years.

What is the dividend of PCI Biotech Holding A?

For the upcoming 12 months, dividends amounting to 0 NOK are expected. This corresponds to a dividend yield of 0 %.

In which sector is PCI Biotech Holding A located?

PCI Biotech Holding A is assigned to the 'Health' sector.

Wann musste ich die Aktien von PCI Biotech Holding A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PCI Biotech Holding A from 11/6/2024 amounting to 0 NOK, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did PCI Biotech Holding A pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of PCI Biotech Holding A in the year 2023?

In the year 2023, PCI Biotech Holding A distributed 0 NOK as dividends.

In which currency does PCI Biotech Holding A pay out the dividend?

The dividends of PCI Biotech Holding A are distributed in NOK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PCI Biotech Holding A

Our stock analysis for PCI Biotech Holding A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PCI Biotech Holding A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.